Sinovac Biotech Ltd. is a profitable biopharmaceutical company headquartered in Beijing, China. The Company focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. Sinovac received approval in 2009 for its H1N1 influenza vaccine, PANFLU.1 and has commenced fulfilling orders from the Chinese Central Government pursuit to the government stockpiling program. Sinovac was the first company worldwide to receive approval for H1N1 influenza vaccine. Sinovac has a robust pipeline of new vaccine products under development. The Company is currently developing vaccines for Enterovirus 71 (EV 71), Pneumococcal Conjugate Vaccine, Hib, and Meningitis. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for an independently developed inactivated animal rabies vaccine.